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Abstract
Background Atopic eczema (also known as eczema) is a chronic, inflammatory skin condition that often afflicts
patients’ health and well-being. The Harmonising Outcome Measures for Eczema (HOME) initiative recommends that
‘long-term control of eczema’ is measured in all clinical trials 3 months or longer in duration. However, little has been
published on what eczema control means to those living with or treating atopic eczema.
Objectives To (i) develop understanding of what eczema control means to patients, carers and clinicians and (ii)
explore the feasibility and acceptability of different ways of measuring eczema control in the long term.
Methods Online focus groups explored patients/carers experiences in the UK, the United States, the Nether-
lands, France, Sweden and Japan, and an international online survey gathered views of clinicians. The framework
method was used to analyse the focus groups, and thematic analysis was used to analyse survey data. All find-
ings were integrated into a theoretical framework to create overarching themes that cut across these diverse
groups.
Results Eight focus groups with patients (16 years+) and eight groups with carers of children took place (N = 97).
Sixty-two people took part in the survey. Eczema control was described as a multifaceted construct involving
changes in disease activity, the treatment and management of the condition and psychological, social and physical
functioning. Patient/carer measurement allows personal accounts and frequent measurement, whilst clinician mea-
surement was deemed less subjective. The burden on patients/carers and issues for analysing and interpreting data
should be considered.
Conclusions This study formed the basis of judging the content validity and feasibility of measurement instruments/
methods to assess control of eczema in clinical trials. This online approach to an international qualitative study is an
example of how core outcome set developers with limited resources can engage with multiple stakeholder groups on an
international basis to inform consensus meeting discussions.
Received: 30 September 2018; Accepted: 19 December 2018
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2019, 33, 1124–1132
This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
DOI: 10.1111/jdv.15475 JEADV
Conflict of interest
All authors are members of the Harmonising Outcome Measures for Eczema (HOME) initiative. Dr Barbarot has
received research grants from Pierre Fabre Laboratory and Fondation pour la dermatite atopique; personal fees
from Bioderma, Laboratoire La Roche Posay, Sanofi-Genzyme, Leo Pharma and Abbvie; and non-financial
support from Abbvie, Novartis and Janssen.
Funding source
This study was partially supported by PhD studentship of Laura Howells awarded by the British Skin Foundation
[ref: 8016]. The funders had no role in the data collection, interpretation and reporting of this study.
Introduction
Atopic eczema (syn: eczema, atopic dermatitis) is a chronic,
inflammatory skin condition characterized by periods of remis-
sion and relapse.1 An international survey found that 75% of
patients and caregivers rated being able to effectively control
their eczema as the most important factor contributing to an
improvement to their quality of life.2
The Harmonising Outcome Measures for Eczema (HOME)
initiative is an international collaboration developing a consen-
sus and evidence-based core outcome set for atopic eczema clini-
cal trials.3–7 The HOME initiative recommends that ‘long-term
control of eczema’ is measured in all clinical trials 3 months or
longer in duration.3,5 The first step for HOME to be able to rec-
ommend instrument(s) to measure this domain was to conduct
international studies to gather patient and clinician perspectives
on long-term control of eczema.
Content validity is essential for an instrument to be
selected for inclusion in a core outcome set and is defined as
‘the degree to which the content of a health related patient
reported outcome instrument is an adequate reflection of the
construct to be measured’.8,9 A key initial step in establishing
content validity is defining the construct to be measured. A
construct is differentiated from a general concept, as it is a
well-defined subject of measurement that has a clear and pre-
cise meaning.10 A conceptual model of the construct is then
developed to allow judgement of whether an instrument ade-
quately reflects the concepts relevant to the construct of
interest.9 Qualitative research helps to build a definition of a
construct that authentically and comprehensively reflects
patient experiences.11
This study aimed to facilitate evidence-based discussions
within HOME about how to define and measure ‘long-term
control of eczema’ and enable assessment of the content validity
of existing outcome measurement instruments. The study objec-
tives were (i) to understand what long-term control of eczema
means to people living with atopic eczema (including adults
with eczema and parents/carers of children with eczema) and
people treating eczema (clinicians/researchers) and (ii) to
explore the potential feasibility and acceptability of different
ways of measuring long-term control of eczema.
Methods
Study design
To obtain the perspectives of patients/carers and clinicians treat-
ing atopic eczema, online focus groups and an online survey
were carried out respectively.
Online focus groups with patients/carers
Participant selection Adults with eczema and parents, legal
guardians or carers of children with eczema were included in
the online focus groups, hereafter referred to as patients/carers
for brevity. The term ‘patients’ refers to people who are seek-
ing or receiving health care.12 As we recruited through a vari-
ety of different platforms and not necessarily healthcare
settings, participants in these studies could more correctly be
referred to as ‘people with eczema’. However, we sometimes
refer here to ‘patients’ for brevity. The sampling strategy
aimed to purposefully include a diversity of participants
regarding age, sex, ethnicity, eczema severity and disease dura-
tion, but convenience was also a factor.13 Recruitment was via
social media or approaching patients in clinics and varied by
country (See Table S1 in Supplementary Materials for details
of methods by country).
Procedures and materials Online focus groups were conducted
via text-based chat room websites between August 2016 and
June 2017 in the UK, the Netherlands, France, Sweden, the Uni-
ted States and Japan. Local teams conducted the data collection
in their own country and native language, supported by the UK
team, following the format of the initial UK-based focus groups.
Full details of the procedure of the UK focus groups have been
described elsewhere.14 Table S1 in Supplementary Materials
highlights key aspects of the procedure for each country. Each
focus group followed a common semi-structured topic guide
that was developed by the UK-based authors (Figure S1 in Sup-
plementary Materials). Questions were open-ended, for example,
‘How would you decide if a treatment has been working well or
not?’ and followed up with prompts to elicit further information
from participants. The term ‘long-term control’ was initially
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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avoided by the facilitators to allow individuals to refer to this
concept using language that was meaningful to them.
Analysis The principles of framework analysis were used to
analyse the transcripts thematically.15 Framework analysis is a
method that sorts data into key themes using the five steps of
familiarization, identifying a theoretical framework, indexing,
charting, and mapping and interpretation.15 Each country used
a thematic framework to map findings to the subthemes that
were based on the findings from the UK focus groups and also
highlight findings that did not fit within the framework.14 This
was done in the native language of the researchers. The detailed
UK findings were not shared with the other groups until they
had analysed their findings. A summary and key quotes were
produced in English by each country. The UK team collated and
compared the data from all countries in a thematic framework.
Any areas of uncertainty were discussed with the researchers
who collected the data.
Online survey of HOME membership
Participant selection All members of HOME were invited to
participate. HOME is an open-invitation, international, multi-
stakeholder group including clinicians (mainly dermatologists),
methodologists, patients, patient representatives and the phar-
maceutical industry (http://www.homeforeczema.org/).
Materials and procedures This online survey took place during
September and October 2016 using SurveyMonkey Inc. soft-
ware.16 Using mainly open questions with free-text responses,
participants were asked what they considered to be long-term
control of eczema and their views on different ways of measuring
long-term control (Figure S2 in Supplementary Materials) iden-
tified from a systematic review.17
Analysis Thematic analysis was used to analyse textual data.18
J.R.C compiled the themes and I.N and L.H reviewed the
themes, which were then discussed and revised.
Combining the focus group and survey findings
L.H and J.R.C combined the themes from the online patient/
carer focus groups and the clinician survey into an overarching
thematic framework. These themes were then compared with
original data sources and initial coding confirmed with all
authors.
Results
Participant characteristics
Sixteen online focus groups took place including 97 patients/
carers across six countries. Table 1 provides participant
demographics.
Sixty-two out of 251 HOME members from sixteen countries
completed the online survey, a response rate of 25%. Most
(81%) were clinicians, plus five methodologists/non-clinical
researchers and seven patient representatives. Since this survey
principally represents the views of clinicians, this group is here-
after referred to as clinicians for brevity. Sixteen countries across
six continents were represented (Fig. 1).
Overarching themes
The results can be structured into two overarching themes: (i)
long-term control as a multifaceted construct and (ii) long-term
control is complex to measure. Illustrative quotes that link
themes to the data are presented in Tables 2 and 3.
Long-term control as a multifaceted construct Most partici-
pants described multiple related aspects of atopic eczema when
thinking about ‘what is long-term control of eczema?’ which
divide into four key subthemes (Fig. 2).
Long-term control as disease activity. Patients/carers and clini-
cians frequently described long-term control as a reduction in
disease activity. Signs and symptoms such as the level of itch,
pain and redness were often mentioned, although patients with
more severe atopic eczema were also concerned about complica-
tions such as infection and bleeding. Clinicians used terms such
as reduced intensity, minimal signs and/or symptoms or mini-
mal disease activity. Differences in some symptoms by country
were noted, for example only participants in France discussed
‘smoothness of skin’ as an indicator of control.
Disease activity in relation to flares of activity was also
described. A reduction in the intensity, number, frequency and
duration of flares was all parameters suggested as indicators of
disease control. However, the concept of ‘flares’ was not seen as
universally useful, as a flare was difficult to define and did not
always correlate with disease activity. For example, those with a
continually high level of disease activity may not experience
flares, despite having uncontrolled atopic eczema.
The experience of long-term control goes beyond the skin. A posi-
tive impact on daily activities was considered important to
patients/carers and clinicians. Patients/carers reported a wide
range of daily activities that were affected by atopic eczema, but
these varied amongst countries. For example, in the UK, wash-
ing, exercise and clothing choice were discussed, whereas in
Japan, it was disturbance of concentration whilst reading books
and watching TV. Scratching, sweating, pain, sleep disturbance
and lack of ability to concentrate were amongst the ways that
patients and carers described atopic eczema having an impact on
their daily life.
The emotional impact of uncontrolled eczema was raised by
patients/carers, who often reported high levels of distress when
eczema was uncontrolled. Feeling frustrated, miserable and
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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‘stressed’ when eczema was uncontrolled, apprehensive about
the return of flares and the social impact on patients and their
families were all mentioned. Feeling embarrassed or receiving
comments from others were discussed, particularly when the
eczema was on a visible area such as the face. Some patients/car-
ers felt that eczema controlled their lives and prevented social
activities, such as visiting friends and family and school atten-
dance. Clinicians also described the impact of uncontrolled
eczema on patient’s quality of life.
Long-term control linked to treatment and management
decisions. Long-term control was also linked to treatment use by
patients/carers and clinicians in all countries. Reducing treat-
ment and returning to maintenance treatment were indicators of
regaining control. Using only maintenance treatment and ability
to self-manage were indicators of ongoing control. Seeking help
from a doctor, stepping up treatment and increasing the amount
or frequency of treatment were all described as indicators that
the disease was uncontrolled.
Control is an individual experience. Control of eczema was lar-
gely considered to be an individual experience. Individual
patients/carers reported different aspects of the disease as being
representative of a lack of control, such as specific symptoms,
Table 1 Demographic info of online focus group participants
UK The Netherlands France Sweden USA Japan All countries
Participants, N 37 15 9 15 8 13 97
Patients, N 19 7 5 7 4 10 52
Parents, N 18 8 4 8 4 3 45
Focus groups, N 6 2 2 2 2 2 16
Self or parent-reported sex, n
Male 13 6 4 4 0 8 35
Female 24 9 5 4 8 5 55
Unknown 0 0 0 7 0 0 7
Self or parent-reported age in years, n
≤5* 12 5 0 4 0 2 23
6–11* 5 1 4 2 3 1 16
12–15* 0 2 0 2 1 0 5
16–25 7 0 0 2 3 4 16
26–40 6 1 2 2 0 0 11
40 6 6 3 2 1 6 24
Unknown 1 0 0 1 0 0 2
Self or parent-reported ethnicity, n
White 33 14 9 15 4 0 68
Asian 1 0 0 0 2 13 15
Black 0 0 0 0 1 0 1
Mixed 3 1 0 0 1 0 5
Unknown 0 0 0 0 0 0 0
Self or parent-reported years since eczema diagnosis, n
≤5 13 5 1 5 0 3 27
6–11 6 1 3 2 3 0 15
12–15 0 2 0 1 0 2 5
16–25 6 0 2 3 4 4 19
26–40 5 2 1 3 0 2 13
>40 5 5 1 1 1 2 15
Unknown 2 0 1 0 0 0 3
Self or parent-reported current disease severity, n
Clear 2 0 1 0 0 0 3
Almost clear 4 2 2 3 0 2 13
Mild 8 4 5 7 1 4 29
Moderate 16 5 1 3 3 4 33
Severe 6 4 0 1 4 3 18
Very severe 1 0 0 0 0 0 1
Unknown 0 0 0 1 0 0 1
*Participants were carers for all aged under 16 years.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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the need to increase treatment or the impact on particular
aspects of life. The level at which disease activity or impact rep-
resents control varied between individual patients/carers. Some
expressed that feeling the eczema has ‘completely receded’ would
represent control, whereas for others, a reduced and acceptable
level of disease activity was considered controlled. Clinicians
often linked control to being what is acceptable to the individual
patient such as ‘can live with’ or that is ‘acceptable to the
patient’.
Long-term control is complex to measure Patients/carers and
clinicians also discussed what they felt was important when mea-
suring long-term control, and the sometimes opposing views
reflect the complexity involved in measuring this multidimen-
sional construct.
Who should measure long-term control? Experience vs.
standardization. The majority of patients/carers felt strongly
that they were best placed to understand and measure their
own (or their child’s) eczema and could measure disease
activity between visits to their doctor. Some patients/carers
felt clinicians should also measure the eczema, as they have
expertise, experience and are less likely to be subjective.
Clinicians acknowledged the importance of patient-reported
outcomes as an important way of capturing aspects of the
disease that cannot be assessed by a clinician, but for mea-
suring long-term control in clinical trials, they were also
concerned about potential for bias, reproducibility and scien-
tific acceptability, and discrepancies between patient-reported
and clinician-reported outcomes. These findings point to a
trade-off between measuring aspects of control that only
patients/carers can assess that captures their everyday experi-
ence versus having a more standardized method of
measuring long-term control that can be assessed by inde-
pendent observers.
The burden and feasibility of measuring long-term control. Many
patients/carers raised concerns about the time and effort
required to measure long-term control comprehensively,
whereas some, particularly parents of children with eczema, were
prepared to go to great lengths to ensure that the level of control
was captured accurately and frequently. Clinicians also high-
lighted the potential burden of frequent measurement on
patients/carers resulting in the generation of large amounts of
potentially redundant data. In the United States, the Netherlands
and the UK, patients/carers discussed the role that technology
such as smartphone applications and photographs could help
them measure their eczema more frequently and for long periods
of time.
Discussion
This study suggests atopic eczema control is a multifaceted
construct involving changes in the signs and symptoms of
eczema, psychological, social and physical functioning, and
the treatment and management of the condition. Indicators
of control and the acceptable level of control can vary
between individuals. Both patient-reported and clinician-
reported outcomes were considered important when measur-
ing atopic eczema control.
The multidimensional nature of atopic eczema control is
reflected in a systematic review of how long-term control has
previously been captured in clinical trials.17 Ninety-one per
cent of trials captured long-term control by including
repeated measurement of outcomes, such as clinical signs,
quality of life and itch, whilst the use of atopic eczema medi-
cations or flares (most commonly measured as time to first
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survey respondents.
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flare or number of flares) was reported in approximately a
quarter of trials.17 Although clinical trials have captured indi-
vidual subdomains identified in this study as being important
to patients/carers and clinicians, long-term control has not
routinely been captured as a unified construct using a single
instrument.
Table 2 Illustrative quotes for Theme 1
Theme 1: Long-term control is a multifaceted concept
Subthemes Illustrative quotes (patients/carers) Illustrative quotes (clinicians/researchers)
(1a) Disease activity
Improved signs and
symptoms
I feel long-term control means less pain, less itch,
less scratch – adult, Japan
Achievement and maintenance of a low level of symptoms
and signs of AD over time – clinician, Germany
Flares My skin really hates me. Usually when it has completely
receded, I am still waiting for this eczema to die
down completely. – adult, UK
A treatment plan that prevents flares for a longer period of
time (years) – Clinician, Denmark
(1b) Beyond the skin
Emotional impact Her whole demeanour changes too – weepy, fiery
temper, generally sad. – carer, UK
In case of big flare, my skin gets worse and worse
spontaneously even though I do not scratch. I feel quite
depressed in this process – adult, Japan
Social impact Children at school can be quite unkind when it’s
sore looking – carer, UK
How they interact, their developmental markers,
how much socialisation they get, for us when his
skin is bad it’s the socialising and getting out of the
house that suffers – carer, UK
Re-establishment of normal sleep patterns Re-establishment
of normal social activities and ADLs [activities of daily living].
Re-establishment of normal family dynamics – clinician,
South Africa
Family impact ‘center of our lives’ –carer, USA
Effect on my day
(including the impact
of scratching
and loss of
concentration)
I would say how much I feel my eczema is bothering
me in everyday life, what you might be doing differently
because of your eczema – adult, UK
and then I’d spend my time staring into space, itching,
feeling sorry for myself and unable to snap out of it – adult, UK
Permanent sensation of scratching non-stop – adult, France
Living with eczema of a tolerable level without flares that start
to interfere with work and play – clinician, UK
Increase in symptoms, itching, scratching behaviour that
may impact on daily activities/sleep and quality
of life. – clinician, UK
Sleep disturbances It’s important to me to create more rest in the long-term and
to be able to sleep well. Then I have more energy to do
my daily things – adult, The Netherlands
How much trouble I have, for example, I get a problem with
sleep when the eczema is at its worst – adult, Sweden
Disease improvement that no longer affects sleep and
daily function that lasts for more than
6 months – researcher, US
(1c) changes in treatment and management
Using only maintenance
treatment
can return to normal maintenance routines – adult, UK No itch; controlled by emollient only. –clinician and
researcher, Japan
Stepping down
treatment
. . .I realize long-term control by frequency of TCS application.
While maintaining by tapering frequency of TCS, I recognize
long-term control by no flare despite less
frequent TCS. – adult, Japan
The end of using the rescue medication, because overall
disease severity is back to pre-flare levels. – clinician,
Germany
Self-management
of the eczema
I guess so. We see the doctor more during a bad patch,
but when I can manage it at home we see him less. I only go
to him if I need him when it’s beyond
me level of helping. – carer, UK
Self-management of control of eczema flares – researcher,
Germany
(1d) An individual experience
A level of eczema
acceptable to me
I think everyone has his own definition of ‘control’. For me the
bar is set fairly low. I will have itch every day and I accept it.
As long as it’s not constantly there. – Adult, Netherlands
Over time I have been taught by patients that individually,
patient satisfaction with their skin and the treatments used
varies enormously and what for me as a clinician is poor
control is entirely acceptable for a patient who has reached a
level of control that they feel manageable and which does not
interfere with their life style psychosocial health or general
health (read adverse effects especially). How does one
integrate measures of this sort into trials and give them
meaning? – clinician and researcher, South Africa
Some quotes have been translated into English from another language. Spelling and grammar have been edited for ease of reading.
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There is no agreed definition of an eczema flare, although
many definitions have been proposed and used in trials often
with little validation.19,20 However, our study suggests that
eczema control should be viewed by patients/carers and clini-
cians as a broader concept than these previous definitions. Fur-
thermore, we identified how treatment escalation in response to
Table 3 Illustrative quotes for Theme 2
Theme 2: Long-term control is complex to measure
Subthemes Illustrative quotes from patients/carers Illustrative quotes from clinicians/researchers
(2a) Who measures
long-term control
You know your own body and eczema best, a doctor has expertise
and experience. – adult, The Netherlands
Has to be you. SO subjective a topic, and nurses’ [and] doctors can
only observe so much – and not the effects it has personally! –adult, UK
Recording of observed signs in parallel with
patient-reported symptoms and QoL will add
information. Taken together, these measures
would probably be judged by many as more
robust and valid. – clinician and
researcher, Sweden
These measures might be more standardized
across a population. – clinician and researcher,
United States
(2b) The burden and
feasibility of measuring
long-term control
Again it depends on each child, but certainly more frequently than the usual
3 months between consultant visits; we can be fine in the morning as
horrendous by bedtime. – parent, UK
I do not want to observe every bad aspect of my skin,
as it makes me depressed.
I never want to take a picture of worsening skin. I think we should look
at the better aspects. – adult, Japan
The time interval might depend on individuals needs and severity
of eczema. – adult, Sweden
Motivation of patient to describe regular frequent
diary is needed. Reliability that the patient
regularly and surely describe each outcome
is doubtful. – clinician, Japan
[Discussing concept of well-controlled weeks]
Difficult to define/assess, Might be difficult to
assess in a standardised way and might result in
difficulties to merge data/compare trials – clinician
and researcher, Sweden
Some quotes have been translated into English from another language. Spelling and grammar have been edited for some quotes for ease of reading.
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a loss of control is subject to differences between individuals
depending on their access to healthcare resources, concerns they
may have about using certain treatments and the type of treat-
ment (i.e. topical or oral) that they are using.
The variability between patients regarding the level of control
considered to be acceptable, highlighted by both patients/carers
and clinicians, presents a challenge for measuring eczema con-
trol. What constitutes control for an individual with eczema
may be driven by their expectations of the disease course, their
treatment and the degree to which they have accepted having the
disease and the lack of a cure. It is possible that expectations
about the level of disease control in eczema may be altered in the
future by advances in treatments. It is important to consider
how the expectations of the patient/parent may impact measures
of eczema control. For a patient/parent-reported outcome, there
may be changing standards depending on level of adjustment to
the condition.
Both patient/carer and clinician-reported outcomes were con-
sidered important in the measurement of eczema control. There
is an increasing acceptance within the medical community of
patient-reported outcome measures and a patient-centred
approach to health care, and a review showed that patient/par-
ent-reported symptoms were reported in 78% of atopic eczema
clinical trials.21 However, with both patient-reported and clini-
cian-reported measures, consideration of the burden and feasi-
bility of measurement is needed.
Strengths and limitations
This study was a pragmatic approach to collecting qualitative
data on an international scale from a range of stakeholders. The
innovative online approach provides a low-cost and rapid alter-
native to other more traditional methods of opinion gathering
such as face-to-face focus groups, whilst still creating a support-
ive environment where discussion could be prompted. However,
one challenge with the online data collection is that the
responses could be brief. The learning from the initial UK-based
online focus groups was shared with other authors running the
subsequent online focus groups in other countries to elicit more
detailed responses and prompt a coherent discussion amongst
participants.14 A convenient online survey using mainly open-
text responses was used to gain the clinician perspective. This
method was considered appropriate because HOME members
are familiar with the concepts being discussed and responses
were generally clear and relevant. Only 25% of the HOME mem-
bership took part in the survey, and it is possible that views may
not have been representative of the entire HOME membership.
However, the findings from this study informed decisions at the
next HOME meeting, therefore allowing HOME members who
did not participate in the survey further opportunity to input
into HOME consensus decisions.
Although the sampling was partially convenience-based due
to restraints on time and resources, participants with diverse
characteristics were still included. However, people with mild
atopic eczema and primary care practitioners treating atopic
eczema were under-represented. These two groups respectively
constitute the majority of people with eczema and deliver the
majority of atopic eczema care.22 The availability of resources
also resulted in a predominance of participants in Western
countries, and further efforts are needed to engage patients, par-
ents and clinicians across different continents to ensure the
cross-cultural validity of the HOME initiative’s recommenda-
tions.
Implications and future directions
To our knowledge, this is the first international qualitative study
to investigate what long-term control of eczema means to
patients, carers and clinicians. It provides evidence for develop-
ing a standardized, consensus-based definition of long-term con-
trol of eczema by the HOME core outcome set initiative. The
implementation of the core outcome set will allow standardiza-
tion of measures across atopic eczema trials and increase the
ability to synthesis and compare results across multiple trials.
Understanding long-term control from different stakeholder
perspectives will lead to improvements in how long-term control
is measured in clinical trials. This study directly informed dis-
cussions about the content validity and feasibility of different
methods of measuring long-term control at the HOME V con-
sensus meeting, allowing the HOME group to move towards
consensus on standardizing the measurement of this domain.7
Those assessing the quality of existing measurement instruments
or developing measurement instruments of atopic eczema con-
trol could use the findings of this study to inform decisions
about the content validity of the instrument. The results of this
study are currently being used to inform the development of an
eczema control instrument. Although this study was aimed to
inform measurement of eczema control in clinical trials, it may
also be appropriate to inform measurement in routine clinical
settings.
Conclusions
Patients, carers and clinicians across multiple countries view
long-term control of eczema as a multifaceted construct involv-
ing changes in disease activity, the treatment and management
of the condition and psychological, social and physical function-
ing. This online approach to an international qualitative study is
an example of how core outcome set developers with limited
resources can engage with multiple stakeholder groups on an
international basis to inform consensus meeting discussions.
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